Bexsero uptake high
July 30, 2014
NOVARTIS has said its
meningococcal B vaccine Bexsero
(PD 07 Mar) has seen high uptake
in its first large-scale public
vaccination program in Quebec’s
Saguenay-Lac-Saint-Jean region.
More than 45,000 infants,
children and adolescents had
received at least one dose, reaching
81% of the target population of
the campaign in the three months,
Novartis said.
Reported adverse events had
been consistent with what had
been reported in clinical trials, a
Novartis spokesperson said.
In Australia, the vaccine was
reviewed by the Pharmaceutical
Benefits Advisory Committee this
month, with outcomes expected
to be made public on 22 Aug, a
Novartis spokesperson said.
It was in talks in the coming
weeks about licensure in NZ.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 14
